Question Bank › Conviction backed by things in hand

Conviction backed by things in hand

Conviction backed by things in hand: management stakes the next leg of growth on evidence it already possesses, not cond

Calls Tested
396
Answered YES
29
Hit Rate
7.3%
rare by design

POSCO Holdings Inc. (PKX) — this company's answers

NO on the Q3 2022 call 2022-10-24 D
The model's full reasoning — Q3 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否明确表达了对未来业务显著提升的信心,并且这种信心是否基于公司已经拥有的具体证据。 首先,关于“明确信心”部分:管理层在电话中提到了多个未来计划,如阿根廷锂项目二期投资、镍精炼厂建设、Gwangyang锂工厂等,并预计在2025年达到盈亏平衡。这些表明管理层对未来增长有明确预期。但需要看是否“清晰表达”了业务将“显著提升”到更高水平,而不仅仅是持续或恢复。 其次,关于“具体证据”部分:管理层提到了已批准的投资、在建项目、已签署的合同等,如阿根廷二期投资已获董事会批准,镍精炼厂已开工,Gwangyang工厂计划2024年投产等。这些是具体已在进行中的事项,属于“已经拥有”的证据。 然而,电话会议中大量内容是关于洪水灾害后的恢复计划,以及当前市场疲软。管理层对未来的信心更多基于投资和项目,而非当前业务已显著提升。同时,管理层也提到明年上半年可能仍疲软,下半年才好转,这暗示了短期内的不确定性。 综合来看,管理层确实表达了未来增长的计划和信心,但并未明确说“业务将显著提升到更高水平”,更多是长期投资布局。而且证据主要是投资决策和在建项目,而非当前已显现的业务增长。因此,可能不符合“明确信心”和“具体证据”同时具备的条件。 根据规则,如果信心主要基于市场恢复或行业趋势,则回答NO。这里管理层提到市场条件、需求恢复等,但更多是自身项目。但整体上,管理层并未明确说“未来一年业务将显著提升”,而是强调恢复和长期投资。 因此,回答NO。

← Back to the full PKX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that conviction in CONCRETE THINGS THE COMPANY ALREADY HAS IN HAND OR ALREADY HAPPENING — rather than in market conditions, industry recovery, or general optimism? Answer YES when BOTH halves come through together in management's own words, as one coherent posture, in whatever form fits the business: (1) STATED CONVICTION ABOUT A STEP-UP AHEAD. Management plainly conveys that it expects the business to be meaningfully bigger, busier, or stronger over roughly the coming year — not merely steady continuation, and not vague aspiration. The conviction should be unmistakable in how management talks about where the company is headed: confident, specific in direction, and owned by management itself. (2) THE CONVICTION RESTS ON EVIDENCE ALREADY IN THE COMPANY'S POSSESSION. When management explains WHY it is confident, it points to real, present-tense substance — in whatever form fits the industry — such as: business already won, signed, booked, or committed that has not yet fully shown up in results; work, orders, customers, or volumes already arriving or ramping now; a capability, capacity, product, or asset already built or in place that the growth will run through; observable customer behavior already occurring; or progress already made that management can describe concretely. The evidence should be specific enough that management is describing things that exist and can be pointed to, not projections, pipeline hopes, or a market thesis. Where analysts probe or doubt, management responds with this kind of already-real substance rather than with reassurance alone. Answer NO if management's confidence rests mainly on expected market recovery, industry tailwinds, macro improvement, pricing environments, seasonal patterns, or customer sentiment that has not yet converted into anything the company holds. NO if the forward talk is generic optimism, mission language, or big-market framing without concrete present-tense support. NO if the call conveys steady continuation, a defense of weak results, or a turnaround still promised rather than evidenced. NO if the evidence offered is only a raised financial guidance number, an analyst's model, or third-party forecasts. NO if the conviction and the evidence never connect — strong facts reported but no stated step-up ahead, or a stated step-up with nothing in hand behind it. NO if the posture appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
OEC Orion Engineered Carbons S.A. Q4 2022 2023-02-17 B+
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
CUE Cue Biopharma, Inc. Q3 2022 2022-11-14 D
ZVIA Zevia PBC Q1 2022 2022-05-12 B
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
LC LendingClub Corporation Q4 2021 2022-01-26 A
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
KTB Kontoor Brands, Inc. Q3 2021 2021-11-04 A
CMTL Comtech Telecommunications Corp. Q1 2019 2018-12-07 B+
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
ALB Albemarle Corporation Q3 2018 2018-11-08 B
WES Western Midstream Partners, LP Q3 2018 2018-10-31 D
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
INSM Insmed Incorporated Q4 2017 2018-02-23 B
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
FLEX Flex Ltd. Q1 2018 2017-07-28 F
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
ANIP ANI Pharmaceuticals, Inc. Q4 2016 2017-03-02 B+
GPOR Gulfport Energy Corporation Q4 2016 2017-02-14 A
WYY WidePoint Corporation Q3 2016 2016-11-09 D
LBTYK Liberty Global's Q1 2016 2016-05-10 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

CUE · Q3 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up to a meaningfully higher level, citing the recent $30M PIPE financing, Fast Track designation, emerging clinical data from CUE-101 monotherapy and combination trials, and the derisked Immuno-STAT platform as concrete assets already in hand that support advancing toward 2024 clinical development and potential registration paths. They ground this in present-tense facts such as the SITC data, cash runway extension, first CUE-102 patient dosed, and ongoing trial expansions rather than external market or industry conditions.
BFIN · Q1 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up: they have already achieved and exceeded the $40 million quarterly loan growth goal, are targeting $1.125–$1.150 billion in Q2 (with a reach to $1.2 billion by year-end), and expect EPS of $0. 14–$0.16 in Q2 rising $0.03–$0.05 per quarter thereafter, with ROE potentially in the 80s–90s run-rate by early 2023. This conviction rests on concrete, already-real evidence in hand: $45 million loan growth already booked in April 2022 (portfolio now over $1.
ALLY · Q1 2018 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction of a step-up: “we see these metrics meaningfully higher on a year-over-year basis, and that will fully continue over the medium term,” “adjusted EPS growth of 20% to 30% for the year,” “we expect net financing revenue to move higher,” “expect to see acceleration in this line item in Q2 and throughout the rest of 2018,” and “keeps us on the path to delivering our 2018 outlook.” That conviction is grounded in concrete, already-present items: record $9.

More from the question bank

Room to raise the ceilingSelling the shovels to a customer who just gStaircase quarter: best recent period just rCommitment step-up grounded in demand alreadCheap-to-serve incremental businessTheir own money is on the lineAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.